Interpretation of the disease range and clinical therapeutic value of ensifentrine-Ohtuvayre

Ensifentrine (trade name Ohtuvayre) is a new dual phosphodiesterase (PDE3/PDE4) inhibitor that mainly improves respiratory function through bronchial smooth muscle relaxation and anti-inflammatory effects. As an inhaled drug, exefentine can directly act on the airways to improve lung function indicators while reducing systemic side effects, providing a new treatment option for patients with chronic respiratory diseases.

Clinical studies have shown that ensefentin is mainly suitable for patients with chronic obstructive pulmonary disease (COPD), especially moderate to severe patients with dyspnea, airway inflammation and airflow limitation. It can be used as a single inhaled treatment or in combination with existing long-acting bronchodilators or inhaled corticosteroids to improve respiratory symptoms and reduce the risk of acute exacerbations. Some clinical trials are also exploring its potential in asthma and other chronic respiratory diseases.

The clinical value of exefantine lies in its "dual action" mechanism: PDE3 inhibition promotes bronchial smooth muscle relaxation and improves respiratory flow; PDE4 inhibition reduces airway inflammatory response and reduces tissue damage in the course of chronic diseases. This combined mechanism allows patients to significantly alleviate respiratory symptoms while improving their lung function, and is expected to reduce the number of acute exacerbations and improve their quality of life.

In clinical application, exefantine is suitable for patients with moderate to severe COPD and those who have insufficient response to traditional treatments. When using, it is necessary to follow the inhalation administration regulations and regularly monitor the improvement of lung function and symptoms. As more clinical data accumulate, the drug is expected to become an important option in the management of chronic respiratory diseases, providing patients with a safe, efficient and tolerable long-term maintenance treatment.

Reference materials:https://www.drugs.com/